American Pharmacy News
  • State Issues
  • Regulatory
  • Federal Issues
  • Industry
  • Innovation
  • Directory
  • State Issues
  • Regulatory
  • Federal Issues
  • Industry
  • Innovation
  • Directory
  • Home
  • »
  • Stories
  • »
  • Industry

Bracco Imaging invests in health technology company

American Pharmacy News Reports | Apr 9, 2017
Bracco will be better able to give health care leaders and organizations higher standards of patient safety.

Bracco Imaging has invested in PHS Technologies Group to solidify Bracco's role in the industry and increase the scope of its portfolio software applications related to dose management. Read More »

Allergan uncovers potential for using Botox to treat depression

American Pharmacy News Reports | Apr 9, 2017
The women were assigned to three different groups, each of which received a 30 U Botox injection, a 50 U Botox injection, or a placebo.

Popularly known for its ability to enhance facial appearance cosmetically, Botox is now under scrutiny for its possible application for treating major depressive disorder, based on data from a study undertaken by Allergan. Read More »

McKesson Corp. completes acquisition of CoverMyMeds

American Pharmacy News Reports | Apr 6, 2017
McKesson Corp. collaborates with manufacturers, distributors, pharmacies, governments and other entities.

Health care supply distributor McKesson Corp. of San Francisco has completed its acquisition of CoverMyMeds LLC, an Ohio-based source of electronic authorization technology for medical providers and pharmacists. Read More »

Change Healthcare unveils latest clinical support solution

American Pharmacy News Reports | Apr 6, 2017
Change Healthcare strives to support appropriate care while streamlining administrative burdens.

Change Healthcare recently announced the unveiling of InterQual 2017, the company’s flagship clinical decision support solution. Read More »

Phase 2 Evenity study shows promising results

American Pharmacy News Reports | Apr 6, 2017
For the last 12 months of the study, all patients received Evenity for 12 months.

Amgen and UCB recently announced that their phase 2 study for Evenity (romosozumab) showed positive fourth-year results for efficacy and safety as a second course of treatment for postmenopausal women with osteoporosis. Read More »

Bristol-Myers and Incyte to launch Phase 3 studies of drug combination

Mark Iandolo | Apr 6, 2017

Bristol-Myers Squibb Co. and Incyte Corp. have agreed to advance their clinical development program. Read More »

Mylan acquires global rights to Cold-EEZE family of products

American Pharmacy News Reports | Apr 3, 2017
The Cold-EEZE line includes numerous over-the-counter cold remedies.

Mylan N.V. has acquired the global rights to Cold-EEZE, a cold remedy line of products, from ProPhase Labs Inc. Read More »

White paper released on latex allergy risks in health care

American Pharmacy News Reports | Apr 3, 2017
According to the white paper, confusion exists as to products sold with “latex free” or “does not contain latex” labels.

Allergy & Asthma Network and Avella Specialty Pharmacy have released a white paper underscoring latex allergy risks and how that relates to the health care industry. Read More »

Smith Drug Co. supports end to retroactive Medicare D billing

American Pharmacy News Reports | Apr 1, 2017
The billing tactics impact Medicare patients’ costs and CMS disbursements.

In an effort to obtain legitimate protections for seniors, taxpayers and pharmacies, pharmaceutical wholesaler Smith Drug Company recently expressed support for Congressional legislation to prevent benefit managers from billing customers retroactively for Medicare Part D prescriptions. Read More »

Merck KGaA teams with Avillion for psoriasis treatment

American Pharmacy News Reports | Mar 31, 2017
Merck has completed Phase I for the Anti IL-17 A/F Nanobody product.

Merck KGaA has signed an agreement with U.K.-based research and development firm Avillion for an investigative, branded pharmaceutical product designed to address plaque psoriasis, with Avillion’s financial support. Read More »

Pharmacy industry report says price discounts miss mark

Michael Carroll | Mar 30, 2017
Out-of-pocket costs for drugs is dropping overall,  according to the Centers for Medicare and Medicaid Services.

A group representing pharmacy benefit managers is criticizing a report by a drug industry lobbying group that concludes the managers are not passing along drug rebates and discounts to patients. Read More »

Walgreens designates 50 pharmacies as cancer care centers

American Pharmacy News Reports | Mar 29, 2017
Walgreens is positively impacting the health care of over 1.2 million people nationwide living with or in remission from a blood cancer.

Walgreens recently designated over 50 of its nationwide pharmacy locations as cancer specialty centers outfitted with highly trained staff in breast, prostate, colorectal, lung and blood cancer directives with specialized curricula. Read More »

FDA approves Symproic once-daily tablets to treat OIC

American Pharmacy News Reports | Mar 28, 2017
Shionogi also submitted a petition to remove Symproic from controlled substance classification.

Shionogi Inc. and Purdue Pharma L.P.'s Symproic 0.2 mg tablets C-II have been approved by the U.S. Food and Drug Administration for use as a once-daily oral peripherally-acting mu-opioid receptor antagonist medication in treating opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. Read More »

Phase 3 trials for sarecycline meet primary endpoints

American Pharmacy News Reports | Mar 28, 2017
Sarecycline was created to treat patients with moderate to severe acne in the community setting.

Allergan PLC and Parateks Pharmaceuticals' Phase 3 trials of sarecycline met their 12-week primary efficacy endpoints. Read More »

Auryxia by Keryx has been picked up by nation's largest Medicare Part D sponsor

American Pharmacy News Reports | Mar 27, 2017
Auryxia is approved in the U.S. for controlling serum phosphorous levels in patients suffering from chronic kidney disease on dialysis.

Keryx Pharmaceuticals Inc.'s largest Medicare Part D plan sponsor in the United States has added the company’s Auryxia drug to its Medicare Part D plan formularies. Read More »

CVS Health to bring Pharmacists Teach program to Pittsburgh public schools

American Pharmacy News Reports | Mar 27, 2017
CVS Health recently entered a partnership with the University of Pittsburgh School of Pharmacy.

CVS Health recently announced a partnership with the University of Pittsburgh School of Pharmacy and the Pittsburgh Public Schools that will showcase the company’s Pharmacists Teach prescription drug prevention program to public school students with the help of student pharmacists from the university. Read More »

Study shows Repatha can reduce chances of heart attacks and strokes

American Pharmacy News Reports | Mar 27, 2017
This benefit of Repatha starts in patients who take the drug for at least six months.

Based on 27,564 patient cardiovascular outcomes study, Amgen has established that maximally reducing low-density lipoprotein cholesterol levels with Repatha leads to a further reduction in major cardiovascular events, including heart attacks, strokes and coronary revascularizations. Read More »

Data analysis shows Eliquis leads to fewer strokes than warfarin

American Pharmacy News Reports | Mar 25, 2017
The analysis showed Eliquis led to a lower risk of stroke or embolism.

Bristol-Myers Squibb Company and Pfizer Inc. recently announced findings from a real-world data analysis of the U.S. Medicare database that compares risk of stroke or systemic embolism and rate of major bleeding among patients with non-valvular atrial fibrillation who were treated with direct oral anticoagulants versus warfarin. Read More »

CVS Health launches Reduced RX discount program with Novo Nordisk

Mark Iandolo | Mar 25, 2017
 CVS Health and Novo Nordisk will help patients with high out-of-pocket costs afford essential medications.

CVS Health has launched a prescription savings program called Reduced RX that will provide various discounts for certain medications through CVS Caremark directly to patients. Read More »

Teva launches authorized generic of Minastrin 24 Fe as oral contraceptive

Mark Iandolo | Mar 24, 2017
One of every two oral contraceptive prescriptions in the U.S. involves a Teva-marketed product.

Teva Pharmaceuticals Industries Ltd. has launched its authorized generic of Minastrin 24 Fe (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) 1 mg/20 mcg in the U.S. Read More »

  • «
  • 1
  • 2
  • ...
  • 20
  • 21
  • 22 (current)
  • 23
  • 24
  • ...
  • 32
  • 33
  • »
Trending

Sally Pipes, President & CEO of Pacific Research Institute

Pacific Research Institute CEO on 340B Drug Pricing Program: 'Inject some badly needed transparency into 340B'

West Cuthbert, Senior Fellow, American Resolve Action

American Resolve Action Senior Fellow on 340B reform: Oversight 'could prevent billions of dollars in annual waste, fraud, and abuse'

Jonathan Levitt, Founding Partner, Frier Levitt

Frier Levitt partner on CVS Health 340B lawsuits: CVS diverted funds ‘designated to help safety-net hospitals care for the most vulnerable’

B. Douglas Hoey CEO

NCPA supports pharmacy bills being marked up in House committees

Brian Hanna, Executive Director of the Cannabis Regulatory Agency

Cannabis Regulatory Agency seeks new members for diversity, equity, and inclusion workgroup

Copyright © 2026 American Pharmacy News. All Rights Reserved.

  • About
  • Contact
  • Privacy Policy
  • Terms of Service

Alerts Sign-up